Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy
Subscribe to our mailing list
Get our newsletter, Kreos updates and information on our events right to your mailbox.
Market Leading Growth Debt Investor for +25 years
Kreos Capital provides innovative and flexible debt solutions to equity-backed, pan-European and Israeli high-growth companies in the technology and healthcare sectors.
For over 25 years, our sole focus has been to support our ambitious ecosystem with personal, adaptable and responsive financing through every stage of the growth life cycle – from entry level through to late-stage growth including pre and post-IPO.